期刊文献+

p53调控肿瘤与衰老平衡的研究进展 被引量:3

The research progress of p53 regulating the balance of tumor and aging
原文传递
导出
摘要 衰老和肿瘤一直是科学研究的两个重要课题,健康长寿的生活已是人们追求的目标,但是各种因素致使肿瘤的死亡率、患病率日益提升。值得注意的是,衰老和肿瘤这两个看似截然相反的生物学后果之间存在着共享的分子机制,从这些共享机制中找到平衡点,有利于人们提高生活质量、延长寿命。p53在这个过程中有着积极的作用,对大象和小鼠的研究证明高表达且受控制的p53会提高机体对于肿瘤的耐受性,同时还不会导致过早衰老、寿命缩短现象的发生。文章总结了p53在衰老和肿瘤中的调节作用。 Aging and tumor have been two important topics in scientific research, while more and more people pursue health and longevity. The morbidity and mortality of tumor are still increasing because of various factors. Although tumor and aging seem contrary, they also have many similar regulatory mechanisms. Looking for the balance points among these sharing mechanisms maybe help to improve life quality and lengthen lifespan. The gene of p53 plays an active role in these processes. It has been reported that high expression of p53 under control in elephant and mice can increase the body tolerance to tumor, and can't result in the occurrence of premature aging and lifespan shortening. The regulatory effects of p53 in aging and tumor are summarized in this review.
作者 彭雷 刘静 谢晓丽 张继虹 罗瑛 PENG Lei LIU Jing XIE Xiaoli ZHANG Jihong LUO Ying(Molecular Genetics Laboratory of Aging and Cancer, Medical College, Kunming University of Science and Technology, Kunming 650500, Chin)
出处 《生命的化学》 CAS CSCD 2017年第4期515-520,共6页 Chemistry of Life
基金 国家自然科学基金项目(81560601) 云南省自然科学基金项目(KKSY201460019 2014FD011)
关键词 衰老 肿瘤 P53 平衡 aging tumor p53 balance
  • 相关文献

参考文献3

二级参考文献112

  • 1Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009; 10: 30-18.
  • 2Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, et a/. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009; 137: 873-86.
  • 3Hara K, Maruki Y, Long XM, Yoshino K, Oshiro N, Hidayat S, et a/. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002; 110:177-89.
  • 4Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14; 1296-302.
  • 5Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et a/. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-81.
  • 6Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a doubleblind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-56.
  • 7Garcia-Echeverria C. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. Bioorg Med Chem Lett 2010; 20: 4308-12.
  • 8Zhang Y, Zheng XF. mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell cycle 2012; 11: 594-603.
  • 9Don AS, Zheng XF. Recent clinical trials of mTOR-targeted cancer therapies. Rev Recent Clin Trials 2011; 6: 24-35.
  • 10Llovet JM, Hernandez-Gea V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res 2014; 20: 2072-9.

共引文献456

同被引文献21

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部